Antisense modulation of c/ebp beta expression

Abstract

Antisense compounds, compositions and methods are provided for modulating the expression of C/EBP beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C/EBP beta. Methods of using these compounds for modulation of C/EBP beta expression and for treatment of diseases associated with expression of C/EBP beta are provided.

1 . An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding C/EBP beta, wherein said antisense compound specifically hybridizes with and inhibits the expression of C/EBP beta.  
     
     
         2 . The antisense compound of  claim 1  which is an antisense oligonucleotide.  
     
     
         3 . The antisense compound of  claim 2  wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 18, 25, 28, 31, 33, 34, 36, 40, 41, 42, 45, 46, 50, 52, 54, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 68, 69, 70, 71, 72, 73, 75, 79, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 100, 102, 105, 106, 114, 120, 121, 127, 128, 130, 132, 133, 138, 139, 142, 146, 147, 150, 153, 154, 158, 164, 165, 166, 167, 175, 176, 179, 182, 202, 203, 206, 209, 210, 211, 214, 216, 217, 218, 219, 221, 222, 232, 236, 237, 238, 239 or 240.  
     
     
         4 . The antisense compound of  claim 2  wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.  
     
     
         5 . The antisense compound of  claim 4  wherein the modified internucleoside linkage is a phosphorothioate linkage.  
     
     
         6 . The antisense compound of  claim 2  wherein the antisense oligonucleotide comprises at least one modified sugar moiety.  
     
     
         7 . The antisense compound of  claim 6  wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.  
     
     
         8 . The antisense compound of  claim 2  wherein the antisense oligonucleotide comprises at least one modified nucleobase.  
     
     
         9 . The antisense compound of  claim 8  wherein the modified nucleobase is a 5-methylcytosine.  
     
     
         10 . The antisense compound of  claim 2  wherein the antisense oligonucleotide is a chimeric oligonucleotide.  
     
     
         11 . A pharmaceutical composition comprising the antisense compound of  claim 1  and a pharmaceutically acceptable carrier or diluent.  
     
     
         12 . The pharmaceutical composition of  claim 11  further comprising a colloidal dispersion system.  
     
     
         13 . The pharmaceutical composition of  claim 11  wherein the antisense compound is an antisense oligonucleotide.  
     
     
         14 . A method of inhibiting the expression of C/EBP beta in cells or tissues comprising contacting said cells or tissues with the antisense compound of  claim 1  so that expression of C/EBP beta is inhibited.  
     
     
         15 . A method of treating an animal having a disease or condition associated with C/EBP beta comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of  claim 1  so that expression of C/EBP beta is inhibited.  
     
     
         16 . The method of  claim 15  wherein the disease or condition is an inflammatory disorder.  
     
     
         17 . The method of  claim 15  wherein the disease or condition is diabetes.  
     
     
         18 . The method of  claim 15  wherein the disease or condition is an immunological disorder.  
     
     
         19 . The method of  claim 15  wherein the disease or condition is a hyperproliferative disorder.  
     
     
         20 . The method of  claim 19  wherein the hyperproliferative disorder is cancer.